Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Rocket Pharmaceuticals Q3 EPS $(0.75) Beats $(0.81) Estimate

Author: Benzinga Newsdesk | November 06, 2023 05:11pm
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.81) by 7.41 percent. This is a 13.79 percent increase over losses of $(0.87) per share from the same period last year.

Posted In: RCKT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist